Search Results 71-80 of 28145 for B cell lymphomas

1. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

   Clinical Trials · MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL).

2. Mantle cell lymphoma - Diagnosis and treatment - Mayo Clinic

   There the CAR-T cells find and destroy the mantle cell lymphoma cells. ... B-cell lymphomas. National Comprehensive Cancer Network. https://www.nccn ...

3. Hodgkin vs. non-Hodgkin lymphoma: What's the difference?

   Hodgkin lymphoma usually arises from B lymphocytes. Non-Hodgkin lymphomas can arise from B lymphocytes, T lymphocytes or natural killer cells. Hodgkin ...

4. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma - Mayo Clinic

   Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. Participation eligibility. Participant ...

5. CAR-T cell therapy - Mayo Clinic

   Lymphomas are cancers that affect white blood cells in the lymphatic system — a network of organs, glands, vessels and clusters of cells called lymph nodes. B- ...

6. Sorting Out T-Cell Lymphoma - Mayo Clinic News Network

   Although B cells and T cells can give rise to malignancies or lymphomas, T-cell lymphoma is the rarer disease, making up less than 15% of all Non-Hodgkin ...

7. Science Saturday: Quest to unmask an elusive immune cancer - Mayo Clinic News Network

   Among non-Hodgkin lymphomas, the most common is diffuse large B-cell lymphoma, which represents about 30 percent of all lymphomas in the U.S.. Committed to ...

8. A Study Evaluating The Effectiveness Of Axicabtagene Ciloleucel Compared To Standard Of Care Therapy In Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma - Mayo Clinic

   Histologically proven large B-cell lymphoma including the following types defined by WHO 2016 (Swerdlow et al, 2016): · Relapsed or refractory disease after ...

9. T Cell Lymphoma Clinical Trials - Mayo Clinic Research

   The purpose of this study is to evaluate the safety and tolerability of STP938 as a single agent in adult subjects with R/R B-cell and T-cell lymphomas.

10. Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma - Mayo Clinic

    Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma · Share · Facebook · Twitter.